BTK and chronic myelogenous leukemia, BCR-ABL1 positive: Combined BTK and Bcr-Abl inhibition reduced proliferation of TKI-insensitive quiescent (CFSEMax) CD34+ CML stem cells, yielding more cells with no or one division as compared to single IM treatment (Fig. 5e, Supplementary Figs. S13 + S14).